Acromegaly :: FDA Approves New Drug to Treat Rare Disease, Acromegaly

The U.S. Food and Drug Administration today approved Somatuline Depot (lanreotide acetate injection) for the treatment of acromegaly, a rare and potentially life threatening disease in adults caused by abnormal secretion of growth hormone (GH), commonly from a benign tumor located in the pituitary gland located in the brain.

Cosmetic :: American Gynecologists ACOG advises against Cosmetic Vaginal Surgery

So-called “vaginal rejuvenation,” “designer vaginoplasty,” “revirgination,” and “G-spot amplification” procedures are not medically indicated, nor is there documentation of their safety and effectiveness, said The American College of Obstetricians and Gynecologists (ACOG) in a new Committee Opinion published in the September issue of Obstetrics & Gynecology. Moreover, it is deceptive to give the impression that any of these procedures are accepted and routine surgical practices, according to ACOG.

Genome :: Genome study shines light on genetic link to height

Using a new “genome-scanning” method, a team of scientists has identified the first robust link between genes and stature in humans. A single letter change in a gene called HMGA2 enables people who carry it to gain as much as a centimeter in height. The work provides insights into how genes hardwire growth in humans and suggests that finding additional height-related genes may be feasible.

Prostate Cancer :: Grape skin extract inhibits prostate cancer cell growth

Laboratory experiments show that an extract of the skin of muscadine grapes can inhibit growth of prostate cancer cells in the laboratory. Investigators from the National Cancer Institute (NCI), part of the National Institutes of Health, and their research partners also show that muscadine grape skin extract (MSKE) does not contain significant amounts of resveratrol, another grape skin component that has been widely studied and shown to be of potential benefit in preventing prostate cancer growth.

Smallpox :: FDA licenses Acambis’ ACAM2000 smallpox vaccine

Acambis plc (Acambis) (LSE: ACM), a leading vaccine company, announces that the US Food and Drug Administration (FDA) has approved its ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) vaccine for active immunisation against smallpox disease for persons determined to be at high risk for smallpox infection.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack